Skip to main content

Advertisement

SpringerLink
Log in

Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Sustained-release (SR) bupropion enhances quit rates of smokers, generally decreases tobacco withdrawal, and in some studies, reduces craving.

Objective

Investigate the effects of SR bupropion on craving and withdrawal during cigarette abstinence.

Methods

Twenty three smokers participated in three 17-day periods composed of 14 out-patient days followed by 3 (72 h) in-patient days. During the out-patient days, subjects received SR bupropion, placebo, or no drug. During the in-patient days, subjects were abstinent from cigarettes on two occasions while receiving either SR bupropion or placebo and smoked freely during the other occasion. SR bupropion was titrated over the first three out-patient days followed by a fixed dose (300 mg/day) for 14 days (including the three in-patient abstinence days). Cigarette craving, withdrawal, and selected physiological measures were assessed repeatedly over the 72-h periods.

Results

During the 72-h periods, craving intensity was significantly lower with free smoke and SR bupropion than with placebo, and significantly lower during free smoke than during SR bupropion. Overall withdrawal symptoms were significantly lower with free smoke than with either placebo or SR bupropion. Among individual withdrawal symptoms (excluding craving), appetite increase was significantly reduced during SR bupropion compared to placebo. During placebo and SR bupropion, craving intensity displayed a circadian pattern that was different from that observed during free smoke.

Conclusions

SR bupropion reduced craving and appetite increase during smoking abstinence. These findings support the hypothesis that craving and withdrawal symptoms may be controlled by distinct central nervous system pathways.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  • Ahluwalia JS, Harris KJ, Catley D, Okuyemi S, Mayo MS (2002) Sustained release bupropion for smoking cessation in African Americans. A randomise controlled trial. JAMA 288(4):467–474

    Article  Google Scholar 

  • American Psychiatry Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatry Association, Washington, DC, p 244

    Google Scholar 

  • Balfour DJK (1994) Neuronal mechanisms underlying nicotine dependence. Addiction 89:1419–1423

    Article  PubMed  CAS  Google Scholar 

  • Benowitz NL (1993) Nicotine replacement therapy: what has been accomplished—can we do better? Drugs 45:157–170

    Article  PubMed  CAS  Google Scholar 

  • Brandon TH, Tiffany ST, Obremski KM, Baker TB (1990) Post-cessation cigarette use: the process of relapse. Addict Behav 15:105–114

    Article  PubMed  CAS  Google Scholar 

  • Breslau N, Kilbey MM, Andreski P (1992) Nicotine withdrawal symptoms and psychiatric disorders: finding from epidemiologic studies. Am J Psychiatry 149:464–469

    PubMed  CAS  Google Scholar 

  • Cohen J (1988) Statistical power analyses for the behavioral sciences, 2nd edn. Lawrence Erlbaum, Hillsdale, NJ, pp 25–26

    Google Scholar 

  • Cohen J (1992) A power primer. Psychol Bulletin 112(1):155–159

    Article  Google Scholar 

  • Cohen J, Cohen P (1975) Applied multiple regression/correlation analyses for the behavioral sciences. Lawence Erlbaum, Hillsdale, NJ

    Google Scholar 

  • Cooper BR, Wang CM, Cox RF, Norton R, Shea V, Ferris RM (1994) Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism. Neuropsychopharmacology 11(2):133–141

    PubMed  CAS  Google Scholar 

  • Corrigal WA, Franklin KB, Coen KM, Clark PBS (1992) The mesolimbic dopaminergic system is implicated in the reinforcing effects of nicotine. Psychopharmacology 107:285–289

    Article  PubMed  Google Scholar 

  • Cox LS, Tiffany ST, Christen AG (2001) Evaluation of the brief questionnaire of smoking urges (QSU-Brief) in laboratory and clinical settings. Nicotine Tob Res 3:7–16

    Article  PubMed  CAS  Google Scholar 

  • Curry SJ, Mc Bride CM (1994) Relapse prevention for smoking cessation. Review and evaluation of concepts and interventions. Annu Rev Public Health 15:345–366

    Article  PubMed  CAS  Google Scholar 

  • Dalsgrað OJ, Hansen NC, Søes-Petersen U, Evald T, Høegholm A, Barber J, Vestbo J (2004) A multicenter, randomised, double-blind, placebo controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. Nicotine Tob Res 6(1):55–61

    Article  PubMed  CAS  Google Scholar 

  • Davies GM, Willner P, Morgan MJ (2000) Smoking related cues elicit craving in tobacco chippers: a replication and validation of the two-factor structure of the Questionnaire of Smoking Urge. Psychopharmacology 152(3):334–342

    Article  PubMed  CAS  Google Scholar 

  • Di Chiara G (2000) Role of dopamine in the behavioural actions of nicotine related to addiction. Eur J Pharmacol 393:295–314

    Article  PubMed  Google Scholar 

  • Di Chiara G, Imperato A (1988) Drug abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A 85:5274–5278

    Article  PubMed  Google Scholar 

  • Dong J, Blier P (2001) Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology 155:52–57

    Article  PubMed  CAS  Google Scholar 

  • Durcan MJ, Deener G, White J, Johnston JA, Gonzales D, Niaura R, Rigotti N, Sachs DPL (2002) The effect of bupropion sustained release on cigarette craving after smoking cessation. Clin Ther 24(4):540–551

    Article  PubMed  CAS  Google Scholar 

  • Fagerström KO (1978) Measuring degree of physical dependence to tobacco smoking with reference to individualisation of treatment. Addict Behav 3:235–241

    Article  PubMed  Google Scholar 

  • Ferris RM, Cooper BR (1993) Mechanism of antidepressant activity of bupropion. J Clin Psychiatry Monogr 11:2–14

    Google Scholar 

  • Ferry LH (1999) Non-nicotine pharmacotherapy for smoking cessation. Prim Care 26:653–669

    PubMed  CAS  Google Scholar 

  • Fiore MC, Smith SS, Jorenby DE, Baker TB (1994) The effectiveness of the nicotine patches for smoking cessation: a meta-analysis. JAMA 271:1940–1947

    Article  PubMed  CAS  Google Scholar 

  • Fiore MC, Bailey WC, Cohen SJ et al (2000) Treating tobacco use and dependence. Clinical practice guideline. US Department of Health and Human Services Public Health Service, Rockville, MD

    Google Scholar 

  • George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, Kosten TR (2002) A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry 52:53–61

    Article  PubMed  CAS  Google Scholar 

  • Glassman AH (1993) Cigarette smoking: implications for psychiatric illness. Am J Psychiatry 150:546–553

    PubMed  CAS  Google Scholar 

  • Gorin SS, Heck JE (2004) Meta-analysis of the efficacy of tobacco counselling by health care providers. Cancer Epidemiol Biomarkers Prev 13(12):2012–2022

    PubMed  CAS  Google Scholar 

  • Gritz ER, Carr CR, Marcus AC (1991) The tobacco withdrawal syndrome in unaided quitters. Br J Addict 86:57–69

    Article  PubMed  CAS  Google Scholar 

  • Halaris A, Zhu H, Feng Y, Piletz JE (1999) Plasma agmatine and platelet imidazoline receptors in depression. Ann N Y Acad Sci 881:445–451

    Article  PubMed  CAS  Google Scholar 

  • Henningfield JE, Schuh LM, Jarvik ME (1995) Pathophysiology of tobacco dependence. Psychopharmacology: the fourth generation of progress. Raven, New York

    Google Scholar 

  • Hilleman DE, Mohiuddin SM, Del Core MC, Sketch H (1992) Effect of buspirone on withdrawal symptoms associated with smoking cessation. Arch Intern Med 152:350–352

    Article  PubMed  CAS  Google Scholar 

  • Horst WD, Preskorn SH (1998) Mechanism of action and clinical characteristics of three atypical antidepressant: venlafaxine, nefazodone, bupropion. J Affect Disord 51:237–254

    Article  PubMed  CAS  Google Scholar 

  • Hughes JR (2000) New treatments in smoking cessation. CA Cancer J Clin 50:143–151

    Article  PubMed  CAS  Google Scholar 

  • Hughes JR, Glasela M (1993) Transdermal nicotine for smoking cessation. Health Values 17:25–31

    Google Scholar 

  • Hughes JR, Hatsukami DK (1992) The nicotine withdrawal syndrome: a brief review and update. Int J Smok Cessation 1:21–26

    Google Scholar 

  • Hughes JR, Hatsukami DK, Pickens RW, Krahn D, Malin S, Luknic A (1984) Effect of nicotine on the tobacco withdrawal syndrome. Psychopharmacology 83(1):82–87

    Article  PubMed  CAS  Google Scholar 

  • Hughes JR, Stevens WG, Skoog K, Keenan RM, Fenwick JW (1991) Symptoms of tobacco withdrawal. Arch Gen Psychiatry 48:52–59

    PubMed  CAS  Google Scholar 

  • Hughes JR, Higgins ST, Bickel WK (1994) Nicotine withdrawal versus other drug withdrawal syndromes: similarities and dissimilarities. Addiction 89:1461–1470

    Article  PubMed  CAS  Google Scholar 

  • Hurt RD, Sachs DPL, Glover PN, Sullivan CR, Croghan IT, Sullivan PM (1997) A comparison of sustained release bupropion and placebo for smoking cessation. New Engl J Med 337:1195–1202

    Article  PubMed  CAS  Google Scholar 

  • Jamerson BD, Nides M, Jorenby DE, Danahue R, Garret P, Johnston JA, Fiore MC, Rennard SI, Leishow SJ (2001) Late term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy and placebo. Clin Ther 23(5):744–752

    Article  PubMed  CAS  Google Scholar 

  • Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto JL, Daughton DM, Doan K, Fiore MC, Baker TB (1999) A controlled trial of sustained release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685–691

    Article  PubMed  CAS  Google Scholar 

  • Kenford SL, Fiore CM, Jorenby DE, Smith SS, Wetter D, Baker TB (1994) Predicting smoking cessation. Who will quit with and without nicotine patches. JAMA 2718:589–594

    Article  Google Scholar 

  • Killen JD, Fortmann SP (1997) Craving is associated with smoking relapse. Finding from three prospective studies. Exp Clin Psychopharmacol 5(2):137–142

    Article  PubMed  CAS  Google Scholar 

  • Killen JD, Fortmann SP, Newman B, Varady A (1991) Prospective study of factors influencing the development of craving associated with smoking cessation. Psychopharmacology 105:191–196

    Article  PubMed  CAS  Google Scholar 

  • Klesges RC, Klesges LM, De Bon M, Shelton ML, Isbell TR, Klem M (1995) Effects of phenylpropanolamine on withdrawal symptoms. Psychopharmacology 119(1):85–91

    Article  PubMed  CAS  Google Scholar 

  • Koob GF (2000) Neurobiology of addiction. Toward the development of new therapies. Ann N Y Acad Sci 909:171–185

    Google Scholar 

  • Koob GF (2003) Neuroadaptive mechanisms of addiction: studies on extended amygdale. Eur Neuropsychopharmacol 13:442–452

    Article  PubMed  CAS  Google Scholar 

  • Learned-Coughlin SM, Bergström M, Savitcheva I, Ascher J, Schmith VD, Långstrom B (2003) In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry 504:800–805

    Article  CAS  Google Scholar 

  • Leischow SJ, Valente SN, Hill AL, Otte PS, Aickin M, Holden T, Kligman E, Cook G (1997) Effects of nicotine dose and administration method on withdrawal symptoms and side effects during short-term smoking abstinence. Exp Clin Psychopharmacol 5:54–64

    Article  PubMed  CAS  Google Scholar 

  • Meyer JH, Goudling VS, Wilson AA, Hussey D, Christensen BK, Houle S (2002) Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology 163:102–105

    Article  PubMed  CAS  Google Scholar 

  • Miller NS, Gold MS (1993) A hypothesis for a common neuromechanical basis for alcohol and drug disorders. Psychiatr Clin North Am 16:105–117

    PubMed  CAS  Google Scholar 

  • Miyata H, Yanagita T (2001) Neurobiological mechanisms of nicotine craving. Alcohol 24:87–93

    Article  PubMed  CAS  Google Scholar 

  • Patten CA, Martin JE (1996a) Measuring tobacco withdrawal: a review of self-report questionnaires. J Subst Abuse 8(1):93–113

    Article  PubMed  CAS  Google Scholar 

  • Patten CA, Martin JE (1996b) Does nicotine withdrawal affect smoking cessation? Clinical and theoretical issues. Ann Behav Med 18(30):190–200

    Article  Google Scholar 

  • Prochaska JO, Goldstain MG (1991) Process of smoking cessations: implications for clinicians. Clin Chest Med 12:727–735

    PubMed  CAS  Google Scholar 

  • Schneider NG (1994) Smoker Compliant Scale (SCS), revised 1984. In: Kramer JJ et al (eds) 11th mental measurements year book. Buros Institute of Mental Measurements, Lincoln, NE, p 834

    Google Scholar 

  • Schneider NG, Jarvik ME (1984) Time course of smoking withdrawal symptoms as a function of nicotine replacement. Psychopharmacology 82:143–144

    Article  PubMed  CAS  Google Scholar 

  • Schneider NG, Jarvik ME, Forsythe AB (1984) Nicotine vs placebo gum in the alleviation of withdrawal during smoking cessation. Addict Behav 9:149–156

    Article  PubMed  CAS  Google Scholar 

  • Schneider NG, Olmsted RE, Steinberg C, Sloan K, Daims RM, Brown HV (1996) Efficacy of buspirone in smoking cessation: a placebo controlled trial. Clin Pharmacol Ther 60(5):568–575

    Article  PubMed  CAS  Google Scholar 

  • Sciamanna CN, Hoch JS, Duke GC, Fogle MN, Ford DE (2000) Comparison of five measures of motivation to quit smoking among a sample of hospitalised smokers. J Gen Intern Med 15:16–23

    Article  PubMed  CAS  Google Scholar 

  • Shiffman SM, Jarvik ME (1976) Smoking withdrawal symptoms in two weeks of abstinence. Psychopharmacology 30:35–39

    Article  Google Scholar 

  • Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwanltney CJ, Paty JA, Gnys M, Evoniuk G, De Veaugh-Geiss J (2000) The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology 148:33–40

    Article  PubMed  CAS  Google Scholar 

  • Shiffman SR, West RJ, Gilbert DG (2004) Recommendation for the assessment of tobacco craving and withdrawal in smoking cessation trials. Nicotine Tob Res 6(4):599–614

    Article  PubMed  Google Scholar 

  • Silagy C, Lancaster T, Stead L, Mant D, Fowler G (2004) Nicotine replacement therapy for smoking cessation (Cochrane review). In: The Cochrane library, issue 2. Update Software, Oxford

    Google Scholar 

  • Slemmer JE, Martin BR, Damaj MI (2000) Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295:321–327

    PubMed  CAS  Google Scholar 

  • Stolerman IP, Jarvis MJ (1995) The scientific case that nicotine is addictive. Psychopharmacology 117:2–10

    Article  PubMed  CAS  Google Scholar 

  • Tashkin DP, Kanner R, Bailey W, Anderson P, Nides MA, Gonzales D, Dozier G, Patel MK, Jamerson BD (2001) Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet 357:1571–1575

    Article  PubMed  CAS  Google Scholar 

  • Teneggi V, Tiffany ST, Squassante L, Milleri S, Ziviani L, Bye A (2002) Smokers deprived of cigarettes for 72 hours: effect of nicotine patches on craving and withdrawal. Psychopharmacology 164:177–187

    Article  PubMed  CAS  Google Scholar 

  • The Transdermal Nicotine Study Group (1991) Transdermal nicotine for smoking cessation: six-week results from two multicenter controlled clinical trials. JAMA 266:3133–3138

    Article  Google Scholar 

  • Tiffany ST, Cox LS, Elash CA (2000) Effects of transdermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. J Consult Clin Psychol 68:233–240

    Article  PubMed  CAS  Google Scholar 

  • Tønnesen P, Tonstad S, Hjalmason A, Lebargy F, Van Spiegel PI, Hider A, Sweet R, Townsend J (2003) A multicentre, randomised, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. J Intern Med 254:184–192

    Article  PubMed  Google Scholar 

  • Tonstad S, Farsang C, Klaene G, Lewis K, Manolis AP, Perruchoud AP, Silagy C, van Spiegel PI, Astbury C, Hider A, Sweet R (2003) Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomized study. Eur Heart J 24:946–955

    Article  PubMed  CAS  Google Scholar 

  • UNDCP and WHO Informal Expert Committee on the Drug-Craving Mechanism (1992) Report, United Nations International Drug Control Program and World Health Organization Technical Report Series V:92–54439T

  • US Department of Health and Human Services (1988) The health consequences of smoking: nicotine addiction, a report of surgeon general (DHHS publication N CDC 88-8406). US Government Printing Office, Washington, DC

    Google Scholar 

  • Watkins SS, Koob GF, Markou A (2000) Neuronal mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res 2:19–37

    Article  PubMed  CAS  Google Scholar 

  • West R (1992) The nicotine replacement paradox in smoking cessation: how does nicotine gum really work? Br J Addict 87:165–167

    Article  PubMed  CAS  Google Scholar 

  • West R, Hajek P, Mc Neill A (1991) Effect of buspirone on cigarette withdrawal symptoms and short term abstinence rate in a smokers clinic. Psychopharmacology 104:91–96

    Article  PubMed  CAS  Google Scholar 

  • World Health Organization (1997) Tobacco or health. A global status report. WHO, Geneva, Switzerland

    Google Scholar 

Download references

Acknowledgements

The research was funded by GlaxoSmithKline, Italy.

Author information

Authors and Affiliations

  1. GlaxoSmithKline, Via A. Fleming N 4, Verona, 37135, Italy

    Vincenzo Teneggi, Lisa Squassante, Stefano Milleri, Luigi Ziviani & Alan Bye

  2. Department of Psychiatry, School of Medicine, University of Utah, Utah, USA

    Stephen T. Tiffany

Authors
  1. Vincenzo Teneggi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stephen T. Tiffany
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lisa Squassante
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Stefano Milleri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luigi Ziviani
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Alan Bye
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vincenzo Teneggi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Teneggi, V., Tiffany, S.T., Squassante, L. et al. Effect of sustained-release (SR) bupropion on craving and withdrawal in smokers deprived of cigarettes for 72 h. Psychopharmacology 183, 1–12 (2005). https://doi.org/10.1007/s00213-005-0145-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-005-0145-x

Keywords

Search

Navigation